Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Angela Äbelö"'
Autor:
Koen Jolling, Angela Äbelö, Nicolas Luyckx, Marie‐Anna Nandeuil, Mirco Govoni, Massimo Cella, Andreas Lindauer
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 8, Iss 7, Pp 460-468 (2019)
Concentration‐QTcF data obtained from two phase I studies in healthy volunteers treated with a novel phosphodiesterase‐4 inhibitor currently under development for the treatment of chronic obstructive pulmonary disease were analyzed by means of mi
Externí odkaz:
https://doaj.org/article/ae01ddc87f8f43dc97dba8012c2dab88
Publikováno v:
Journal of Antimicrobial Chemotherapy
Objectives To evaluate the effects of concomitant efavirenz-based ART and genetic polymorphism on the variability in rifampicin and 25-desacetylrifampicin pharmacokinetics. Patients and methods Plasma concentrations of rifampicin and 25-desacetylrifa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d7450c80e9aee1d50470c62ed4c4f55
https://doi.org/10.1093/jac/dkab258
https://doi.org/10.1093/jac/dkab258
Autor:
Carl Amilon, Mikael Boberg, Joel Tarning, Angela Äbelö, Michael Ashton, Rasmus Jansson-Löfmark
Eflornithine is a recommended treatment against late-stage gambiense human African trypanosomiasis, a neglected tropical disease. Standard dosing of eflornithine consists of repeated intravenous infusions of a racemic mixture of L- and D-eflornithine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7e636a5d29359d5294789a05653bd7b
https://doi.org/10.1208/s12248-022-00693-2
https://doi.org/10.1208/s12248-022-00693-2
Autor:
Nicolas Luyckx, Andreas Lindauer, Koen Jolling, Angela Äbelö, Marie-Anna Nandeuil, Mirco Govoni, Massimo Cella
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 8, Iss 7, Pp 460-468 (2019)
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology
Concentration-QTcF data obtained from two phase I studies in healthy volunteers treated with a novel phosphodiesterase-4 inhibitor currently under development for the treatment of chronic obstructive pulmonary disease were analyzed by means of mixed-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6311c9b565d450f0e39290d79b9d4e53
https://doaj.org/article/ae01ddc87f8f43dc97dba8012c2dab88
https://doaj.org/article/ae01ddc87f8f43dc97dba8012c2dab88
Autor:
Jesper Sundell, Michael Ashton, Marie Wijk, Angela Äbelö, Kurt-Jürgen Hoffmann, Emile Bienvenu
Publikováno v:
Antimicrob Agents Chemother
Pyrazinamide is a first-line drug used in the treatment of tuberculosis. High exposure to pyrazinamide and its metabolites may result in hepatotoxicity, whereas low exposure to pyrazinamide has been correlated with treatment failure of first-line ant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e92ffcb0367d5d732b82f3fe1b857e71
https://pubmed.ncbi.nlm.nih.gov/33875424
https://pubmed.ncbi.nlm.nih.gov/33875424
Autor:
Michael Ashton, Kurt-Jürgen Hoffmann, Emile Bienvenu, Sofia Birgersson, Angela Äbelö, Jesper Sundell
Publikováno v:
Journal of Chromatography B. 1105:129-135
Co-infection of tuberculosis in HIV-patients is a major health concern worldwide and especially so in Sub-Saharan Africa. To enhance the study of potential drug-drug interactions when simultaneously treating the two infections, a liquid chromatograph
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5883514a8dd10dabd6d2192cbab771a
https://doi.org/10.1016/j.jchromb.2018.10.027
https://doi.org/10.1016/j.jchromb.2018.10.027
Autor:
Angela Äbelö, Richard M. Hoglund, Umberto D'Alessandro, Stephen A. Ward, Jean-Pierre Van Geertruyden, Halidou Tinto, Maminata Traoré-Coulibaly, Laeticia C. Toe, Joel Tarning, Sofia Birgersson, Innocent Valea
Publikováno v:
Wellcome Open Research
Background: Malaria during pregnancy is a major health risk for both the mother and the foetus. Pregnancy has been shown to influence the pharmacokinetics of a number of different antimalarial drugs. This might lead to an under-exposure in these pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ed887a211f51c473d38c9e4c6f525cf
https://researchonline.lshtm.ac.uk/id/eprint/4654230/1/Population-pharmacokinetics-of-artesunate.pdf
https://researchonline.lshtm.ac.uk/id/eprint/4654230/1/Population-pharmacokinetics-of-artesunate.pdf
Publikováno v:
Pharmacology & Pharmacy. :533-546
Aim: To describe the pharmacokinetic parameters of efavirenz and estimate its clearance (CL/F) accounting simultaneously for drug-drug interactions and CYP2B6 genetic polymorphism. Methods: Genotyping of 516G > T single nucleotide polymorphism of CYP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::264144ec6aa5c6197a5e7487e2d3ba60
https://doi.org/10.4236/pp.2015.611055
https://doi.org/10.4236/pp.2015.611055
Autor:
Angela Äbelö, Michael Ashton, Marelize Swart, Collet Dandara, Agneta Ekman, Emile Bienvenu, Ambroise Wonkam
Publikováno v:
Current Pharmacogenomics and Personalized Medicine. 11:237-246
The cytochrome P450 (CYP450) enzymes play a key role for interindividual variability in drug response. No comprehensive pharmacogenetic data are yet available for the Rwandan population in regards to single nucleotide polymorphisms in CYP450s of majo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bd573dae04f7de58b5134c14bb874a12
https://doi.org/10.2174/18756921113119990006
https://doi.org/10.2174/18756921113119990006
Autor:
Richard M. Hoglund, Ronnatrai Ruengweerayut, Kesara Na-Bangchang, Angela Äbelö, Younis Moussavi, Anurak Cheomung
Publikováno v:
Malaria Journal
Background A three-day course of chloroquine remains a standard treatment of Plasmodium vivax infection in Thailand with satisfactory clinical efficacy and tolerability although a continuous decline in in vitro parasite sensitivity has been reported.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf7acb3e4eaad53c1ce039825ee20128
http://europepmc.org/articles/PMC4772585
http://europepmc.org/articles/PMC4772585